Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.

Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.

Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...

Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However, ...

(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of ...